Under *Part P, Section P–20, Functions,* change the following:.

Under *Chapter PF, Information Technology Service (PF),* delete the titles and functional statements for the *Division of Systems and Network Management (PFC)* and the *Division of Information Systems and Technology (PFH) in their entirety.*

Under *Chapter PE, Administrative Operations Service (PE),* delete item (9) in its entirety and insert a new item (9) as follows: ''(9) a wide range of voice, data, and video services.''

Delete the functional statement in its entirety for the *Division of Technical Support (PEF)* and insert the following: ''The Division manages the Telecommunications Improvement Project and provides a variety of support services for HHS and other customers located in the Washington, D.C. Metropolitan Area and nationwide. (1) Provides the following: voice, data, and video services; visual aids and graphic art services; photography services; library services; printing and reproduction, including operation of copy centers; mail and messenger services; support services for conference room facilities; and (2) carries out printing management and records management responsibilities for the PSC.''

Under *Chapter PC, Financial Management Service (PC),* after the statement for the *Division of Financial Operations (PCE),* add the following title and functional statement:

Division of Information Systems and Technology (PCF) (1) Provides fee-for-service information technology (IT) support to HHS OPDIVs and other Government agencies. Services include providing information from the HHS personnel/payroll system and providing technological support in utilizing evolving IT areas; (2) provides analysis, design, development, implementation and ongoing support of information reporting in various areas, such as personnel and payroll; and (3) provides analysis, design, development, implementation and support in utilizing evolving technology.

This reorganization is effective upon date of signature.

Dated: November 21, 1997.

Lynnda M. Regan,

Director, Program Support Center.

[FR Doc. 97–31718 Filed 12–2–97; 8:45 am]

BILLING CODE 4160–17–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[Document Identifier: HCFA–372]

Agency Information Collection Activities: Proposed Collection; Comment Request

AGENCY: Health Care Financing Administration, HHS. In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

Type of Information Collection Request: Extension of a currently approved collection; *Title of Information Collection:* Annual Report on Home and Community Based Services Waivers and Supporting Regulations in 42 CFR 440 and 441; *Form No.:* HCFA–372 (OMB# 0938–0272); *Use:* States request waivers in order for beneficiaries to have the option of receiving hospital services in their homes. States with an approved waiver under section 1915(c) of the Act are required to submit the HCFA–372 or HCFA–372(S) annually in order for HCFA to: (1) verify that State assurances regarding waiver cost-neutrality are met, and (2) determine the waiver's impact on the type, amount and cost of services provided under the State plan and health and welfare of recipients.; *Frequency:* Annually; *Affected Public:* State, local or tribal government; *Number of Respondents:* 50; *Total Annual Responses:* 223; *Total Annual Hours:* 16,725.

To obtain copies of the supporting statement and any related forms for the proposed paperwork collections referenced above, E-mail your request, including your address, phone number, OMB number, and HCFA document identifier, to Paperwork@hcfa.gov, or call the Reports Clearance Office on (410) 786–1326. Written comments and recommendations for the proposed information collections must be mailed within 60 days of this notice directly to the HCFA Paperwork Clearance Officer designated at the following address: HCFA, Office of Information Services, Information Technology Investment Management Group, Division of HCFA Enterprise Standards, Attention: Louis Blank, Room C2–26–17, 7500 Security Boulevard, Baltimore, Maryland 21244–1850.

Dated: November 24, 1997.

John P. Burke III,

HCFA Reports Clearance Officer, HCFA Office of Information Services, Information Technology Investment Management Group, Division of HCFA Enterprise Standards.

[FR Doc. 97–31623 Filed 12–2–97; 8:45 am]

BILLING CODE 4120–03–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Health Care Financing Administration

[HCFA–1024–N]

Medicare Program; December 15, 1997, Meeting of the Practicing Physicians Advisory Council

AGENCY: Health Care Financing Administration (HCFA), HHS.

ACTION: Notice of meeting.

SUMMARY: In accordance with section 10(a) of the Federal Advisory Committee Act, this notice announces a meeting of the Practicing Physicians Advisory Council. This meeting is open to the public.

DATES: The meeting is scheduled for December 15, 1997, from 8:30 a.m. until 5 p.m. E.S.T.

ADDRESSES: The meeting will be held in Room 800, 8th Floor, Hubert H. Humphrey Building, 200 Independence Avenue, SW, Washington, DC 20201.

FOR FURTHER INFORMATION CONTACT: Jeffrey Kang, M.D., Executive Director, Practicing Physicians Advisory Council, Room 435–H, Hubert H. Humphrey Building, 200 Independence Avenue, S.W., Washington, DC 20201, (202) 690–7874.

SUPPLEMENTARY INFORMATION: The Secretary of the Department of Health and Human Services (the Secretary) is mandated by section 1868 of the Social Security Act to appoint a Practicing Physicians Advisory Council (the Council) based on nominations submitted by medical organizations representing physicians. The Council meets quarterly to discuss certain proposed changes in regulations and

carrier manual instructions related to physicians' services, as identified by the Secretary. To the extent feasible and consistent with statutory deadlines, the consultation must occur before publication of the proposed changes. The Council submits an annual report on its recommendations to the Secretary and the Administrator of the Health Care Financing Administration not later than December 31 of each year.

The Council consists of 15 physicians, each of whom has submitted at least 250 claims for physicians' services under Medicare or Medicaid in the previous year. Members of the Council include both participating and nonparticipating physicians, and physicians practicing in rural and underserved urban areas. At least 11 members must be doctors of medicine or osteopathy authorized to practice medicine and surgery by the States in which they practice. Members have been invited to serve for overlapping 4-year terms. In accordance with section 14 of the Federal Advisory Committee Act, terms of more than 2 years are contingent upon the renewal of the Council by appropriate action before the end of the 2-year term.

The Council held its first meeting on May 11, 1992.

The current members are: Richard Bronfman, D.P.M.; Wayne R. Carlsen, D.O.; Gary C. Dennis, M.D.; Catalina E. Garcia, M.D.; Mary T. Herald, M.D.; Ardis Hoven, M.D.; Sandral Hullett, M.D.; Jerilynn S. Kaibel, D.C.; Marie G. Kuffner, M.D.; Marc Lowe, M.D.; Katherine L. Markette, M.D.; Derrick K. Latos, M.D.; Susan Schooley, M.D.; Maisie Tam, M.D.; and Kenneth M. Viste, Jr., M.D. The chairperson is Kenneth M. Viste, Jr., M.D.

Council members will receive an update on documentation guidelines, physician practice expense, private contracting, physician self referral rules, privacy and confidentiality, regional labaratory carriers, and other issues related to implementation of the Balanced Budget Amendment.

Individuals or organizations that wish to make 5-minute oral presentations on the agenda issues should contact the Executive Director by 12 noon, December 4, 1997, to be scheduled. The number of oral presentations may be limited by the time available. A written copy of the oral remarks should be submitted to the Executive Director no later than 12 noon, December 10, 1997. Anyone who is not scheduled to speak may submit written comments to the Executive Director by 12:00 noon, December 10, 1997. The meeting is open to the public, but attendance is limited to the space available.

(Section 1868 of the Social Security Act (42 U.S.C. 1395ee) and section 10(a) of Pub. L. 92–463 (5 U.S.C. App. 2, section 10(a)); 45 CFR Part 11)

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: November 27, 1997.

Nancy-Ann Min DeParle,

Administrator, Health Care Financing Administration.

[FR Doc. 97–31594 Filed 12–2–97; 8:45 am]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Transgenic Mice That Express Human Cytochrome P450 Genes

AGENCY: National Institutes of Health, PHS, DHHS.

ACTION: Notice.

SUMMARY: The Department of Health and Human Services (DHHS) seeks an agreement with a pharmaceutical or biotechnology company to effectively pursue the development and characterization of transgenic mice that express human cytochrome P450 genes CYP2D6 and CYP3A4. The National Cancer Institute has data suggesting that these animals may be useful in drug development, carcinogen bioassays for risk assessment, and the determination of genetic regulatory mechanisms.

ADDRESSES: Proposals and questions about this opportunity may be addressed to Robert Dell'Orco, Ph.D., Technology Development and Commercialization Branch, National Cancer Institute, Executive Plaza South, Suite 450, 6120 Executive Blvd., Rockville, MD 20852, tel: 301–496–0477, fax: 301–402–2117.

DATES: In view of the important priority of developing new drugs for the treatment of cancer and methods for determining carcinogenic risk, interested parties should notify this office in writing not later that January 2, 1998. Respondents will then be provided an additional 30 days for filing of formal proposals.

SUPPLEMENTARY INFORMATION: ''Cooperative Research and Development Agreement'' or ''CRADA'' means the anticipated joint agreement to be entered into by NCI pursuant to the Federal Technology Transfer Act of 1986 and Executive Order 12591 of April 10, 1987 as amended by the National Technology Transfer Advancement Act of 1995 to collaborate on the specific research project described below.

The National Cancer Institute seeks an agreement with a pharmaceutical or biotechnology company for joint development and evaluation of transgenic mice that express human cytochrome P450 genes CYP2D6 and CYP3A4 in a tissue specific manner that reflects the expression in humans. These two human P450 enzymes are involved in the metabolism of over 75% of the drugs that are now on the market; however, these two enzymes are poorly conserved between rodents and humans. This poor conservation precludes the use of unmodified rodent model systems for the analysis of new drugs with respect to their metabolism by these two enzymes. The development of a human P450 transgenic mouse system will allow for the determination of human metabolism and toxicity of new drugs, the prediction of drug interactions, and the definition of pharmacokinetic parameters in an intact animal system. Additionally, such a system would avoid the utilization of human liver tissue samples which forms the basis of the current methods used in the pharmaceutical industry. The animal model would also form the basis of carcinogen bioassays for human risk assessment and allow for the analysis of P450 gene regulation. In the proposed studies, the animals will be used to determine the tissue specific degradation of drugs. Drugs known through in vitro metabolism studies to be metabolized by CPY2D6 and CYP3A4 will be administered to the transgenic mice, and their pharmacokinetics will be studied.

The Laboratory of Metabolism has many years of experience in cloning and characterizing human P450 genes. More recently, the laboratory has developed a series of knockout and transgenic mice to study various aspects of the role of cytochrome P450 enzymes in carcinogenesis and drug metabolism; and the development of transgenic mice with the human CYP2D6 and CYP3A4 enzymes is a continuation of the laboratory's commitment to this research area. The Laboratory of Metabolism is interested in establishing a CRADA with a company to assist in the continuing development of transgeic animals containing human cytochrome P450 enzymes to study known drug substrates and proprietary drug candidates. The Government will